Hanx Biopharma lines up up to $62M warrant raise for ADC pipeline
What's the deal? Hanx BiopharmaceuticalsDealroom has a profile for this one. Try Dealroom →, a Wuhan-based, Hong Kong-listed drug developer, has agreed with First Shanghai Securities to place up to 13,400,000 unlisted warrants. On full exercise, the deal could raise net proceeds of about HK$486.26 million (roughly $62 million).
How it works: Each warrant carries the right to subscribe for one new share at an initial HK$36, and the warrants themselves are priced at HK$0.36 each. They run for 36 months and, if fully exercised, would represent about 9% of the company's enlarged share capital.
The mechanics: The warrants generate about HK$4.82 million in gross proceeds up front, with up to HK$482.4 million more on full exercise. The new shares require a specific mandate, to be sought at an extraordinary general meeting.
What's the endgame? Hanx develops antibody-drug conjugates (ADC) and immuno-oncology (IO) therapies. It has earmarked the funds for working capital, salaries and operating costs, clinical research, next-generation ADC and IO products, and new molecule and antibody discovery.
What could go wrong? The financing is staged: most of the money only arrives if warrant holders exercise over the 36-month window. Shareholders must also approve the mandate, and TipRanks flags a "Strong Sell" technical signal on the stock.
The signal: The raise marks a step-up from Hanx's previous round, a sign of appetite to fund its ADC and IO pipeline against a HK$3.73 billion market cap. But the warrant structure leaves the full payout contingent on the share price holding up over three years.
Read more: blog.tipranks.com
Image credit: Generated with Gemini
